Cesar Libanati

14.9k total citations · 3 hit papers
150 papers, 9.9k citations indexed

About

Cesar Libanati is a scholar working on Orthopedics and Sports Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Cesar Libanati has authored 150 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Orthopedics and Sports Medicine, 65 papers in Oncology and 61 papers in Molecular Biology. Recurrent topics in Cesar Libanati's work include Bone health and osteoporosis research (99 papers), Bone health and treatments (60 papers) and Bone Metabolism and Diseases (57 papers). Cesar Libanati is often cited by papers focused on Bone health and osteoporosis research (99 papers), Bone health and treatments (60 papers) and Bone Metabolism and Diseases (57 papers). Cesar Libanati collaborates with scholars based in United States, Belgium and Canada. Cesar Libanati's co-authors include Michael R. McClung, José Zanchetta, Andreas Grauer, Andrea Wang, Ethel S. Siris, Javier San Martín, Steven R. Cummings, Matt Austin, Richard Eastell and Ian R. Reid and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Cesar Libanati

142 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

2009 2.4k citations Steven R. Cummings, Javier San Martín et al. profile →
Romosozumab Treatment in Postmenopausal Women with Osteoporosis

2016 1.1k citations Felicia Cosman, E. J. Czerwiński et al. profile →
Romosozumab in Postmenopausal Women with Low Bone Mineral Density

2014 886 citations Michael R. McClung, Andreas Grauer et al. profile →

Peers

Countries citing papers authored by Cesar Libanati

Since Specialization

Citations

This map shows the geographic impact of Cesar Libanati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cesar Libanati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cesar Libanati more than expected).

Fields of papers citing papers by Cesar Libanati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cesar Libanati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cesar Libanati. The network helps show where Cesar Libanati may publish in the future.

Co-authorship network of co-authors of Cesar Libanati

This figure shows the co-authorship network connecting the top 25 collaborators of Cesar Libanati. A scholar is included among the top collaborators of Cesar Libanati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cesar Libanati. Cesar Libanati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate 2024 ·Journal of Bone and Mineral Research ·E. Michael Lewiecki, (unknown), Ludovic Humbert, Cesar Libanati, Mary Oates, Yifei Shi, Renaud Winzenrieth, Serge Ferrari, (unknown)	10
2	Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment 2024 ·Journal of Bone and Mineral Research ·Erik Fink Eriksen, Rogely Boyce, Yifei Shi, Jacques P. Brown, (unknown), Cesar Libanati, Mary Oates, Roland Chapurlat, Pascale Chavassieux	8
3	The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications 2021 ·Osteoporosis International ·Michael Kriegbaum Skjødt, Martin Ernst, Sara Khalid, Cesar Libanati, Cyrus Cooper, Antonella Delmestri, Katrine Hass Rubin, M K Javaid, Daniel Martínez-Laguna, Ervin Tóth, Daniel Prieto‐Alhambra, Bo Abrahamsen	15
4	Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial 2021 ·Journal of Bone and Mineral Research ·Jacques P. Brown, Klaus Engelke, Tony M. Keaveny, Arkadi Chines, Roland Chapurlat, A. Joseph Foldes, Xavier Nogués, Roberto Civitelli, (unknown), Fabio Massari, Cristiano A. F. Zerbini, Zhenxun Wang, Mary Oates, Christopher Recknor, Cesar Libanati	44
5	Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial 2020 ·Journal of Bone and Mineral Research ·Erik Fink Eriksen, Roland Chapurlat, Rogely Boyce, Yifei Shi, Jacques P. Brown, S. Horlait, (unknown), Cesar Libanati, Pascale Chavassieux	29
6	SECULAR TRENDS IN THE INITIATION OF THERAPY IN SECONDARY FRACTURE PREVENTION IN EUROPE: A MULTI-NATIONAL STUDY INCLUDING DATA FROM DENMARK, SPAIN, AND THE UK. 2018 ·Value in Health ·Sana Khalid, Martin Ernst, Katrine Hass Rubin, Daniel Martínez-Laguna, Antonella Delmestri, M K Javaid, (unknown), Cesar Libanati, Ervin Tóth, Bo Abrahamsen, Daniel Prieto‐Alhambra	1
7	Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment 2015 ·Open Repository and Bibliography (University of Liège) ·Serge Ferrari, Cesar Libanati, (unknown), S. Adámi, Jacques P. Brown, Felicia Cosman, E. J. Czerwiński, Luiz Henrique de Gregório, Jorge Malouf, Jean‐Yves Reginster, Nadia Daizadeh, (unknown), (unknown), E. Michael Lewiecki	5
8	Strength at the Lumbar Spine and Hip Improves with Romosozumab Compared with Teriparatide in Postmenopausal Women with Low Bone Mass 2015 ·Arthritis & Rheumatism ·(unknown), (unknown), (unknown), H K Genant, Klaus Engelke, Beatriz Oliveri, Jacques P. Brown, (unknown), (unknown), Andreas Grauer, Cesar Libanati	5
9	Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment 2014 ·Open Repository and Bibliography (University of Liège) ·Serge Ferrari, Cesar Libanati, (unknown), S. Adámi, Jacques P. Brown, Felicia Cosman, E. J. Czerwiński, (unknown), Jorge Malouf, Jean‐Yves Reginster, (unknown), (unknown), (unknown), E. Michael Lewiecki, Steven R. Cummings	1
10	Further reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension 2014 ·Open Repository and Bibliography (University of Liège) ·Serge Ferrari, (unknown), Kurt Lippuner, Carol Zapalowski, P. D. Miller, Jean‐Yves Reginster, Ove Törring, (unknown), (unknown), (unknown), C. D. O’Malley, Cesar Libanati, (unknown), E. Michael Lewiecki	4
11	Romosozumab and Teriparatide Effects on Vertebral Cortical Mass, Thickness, and Density in Postmenopausal Women With Low Bone Mineral Density (BMD). 2014 ·Cambridge University Engineering Department Publications Database ·Tristan Whitmarsh, Graham M. Treece, AH Gee, (unknown), (unknown), Stefan Goemaere, Andreas Grauer, D.A. Hanley, C. Mautalén, Chris Recknor, (unknown), Cesar Libanati, Kenneth Poole	5
12	THE TRANSITORY PTH INCREASE FOLLOWING DENOSUMAB ADMINISTRATION IS ASSOCIATED WITH REDUCED INTRACORTICAL POROSITY: A DISTINCTIVE CHARACTERISTIC OF DENOSUMAB THERAPY 2012 ·Osteoporosis International ·Ego Seeman, Cesar Libanati, Matthew Austin, Roland Chapurlat, Steven K. Boyd, Roger Zebaze, David A. Hanley, José Zanchetta, Andreas Grauer, John P. Bilezikian	1
13	DENOSUMAB REDUCES INTRACORTICAL POROSITY MORE THAN ALENDRONATE IN THE COMPACT-APPEARING CORTEX AND OUTER TRANSITIONAL ZONE 2012 ·Osteoporosis International ·Roger Zebaze, Cesar Libanati, Matthew Austin, John P. Bilezikian, Ego Seeman	1
14	Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis 2011 ·Open Repository and Bibliography (University of Liège) ·Henry G. Bone, R. Chapurlat, Cesar Libanati, Maria Luisa Brandi, Jacques P. Brown, E. J. Czerwiński, M. A. Krieg, Man Zhang, Dan Mellström, S. Radominski, Jean‐Yves Reginster, Heinrich Resch, Jose Andrés Román Ivorra, (unknown), Nadia Daizadeh, Andreas Grauer, Steven R. Cummings, Socrates E. Papapoulos	3
15	A phase 3 study of the efficacy and safety of Denosumab in men with low bone mineral density : design of the ADAMO 2011 ·Open Repository and Bibliography (University of Liège) ·Eric Orwoll, (unknown), Bente Langdahl, R. Chapurlat, E. J. Czerwiński, (unknown), Jean‐Yves Reginster, Alan Kivitz, (unknown), (unknown), Michael A. Bolognese, Henry G. Bone, Östen Ljunggren, Bo Abrahamsen, (unknown), Andreas Grauer, Cesar Libanati, Jesse Hall, Steven Boonen	1
16	FIVE-YEAR DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST TWO YEARS OF THE FREEDOM TRIAL EXTENSION 2011 ·Data Archiving and Networked Services (DANS) ·Socrates E. Papapoulos, Z. Man, Dan Mellström, S. Radominski, Jean‐Yves Reginster, Heinrich Resch, (unknown), Camille Roux, S. R. Cummings, Henry G. Bone, Roland Chapurlat, Maria Luisa Brandi, Jacques P. Brown, E. J. Czerwiński, Nadia Daizadeh, Andreas Grauer, (unknown), Cesar Libanati	9
17	FREEDOM TRIAL: DENOSUMAB IS NOT ASSOCIATED WITH FRACTURE HEALING COMPLICATIONS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS 2011 ·Osteoporosis International ·Silvano Adami, (unknown), Karel Pavelká, Heinrich Resch, C. Roux, Daniel Uebelhart, (unknown), (unknown), Ethel S. Siris, Cesar Libanati, J.D. Adachi, Steven Boonen, (unknown), (unknown), Nigel Gilchrist, George P. Lyritis, (unknown)	2
18	Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first year extension study of the FREEDOM trial 2010 ·Open Repository and Bibliography (University of Liège) ·R. Chapurlat, Socrates E. Papapoulos, Henry G. Bone, Maria Luisa Brandi, Jacques P. Brown, E. J. Czerwiński, Nadia Daizadeh, Andreas Grauer, Christine Haller, Marc-Antoine Krieg, Cesar Libanati, Z. Man, Dan Mellström, S. Radominski, Jean‐Yves Reginster, Heinrich Resch, (unknown), Steven R. Cummings	2
19	Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis 2009 ·Obstetrical & Gynecological Survey ·Steven R. Cummings, Javier San Martín, Michael R. McClung, Ethel S. Siris, Richard Eastell, Ian R. Reid, Pierre Delmas, (unknown), Matt Austin, Andrea Wang, Štěpán Kutílek, Silvano Adami, José Zanchetta, Cesar Libanati, Suresh Siddhanti, Claus Christiansen	41
20	Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial 2008 ·Journal of Bone and Mineral Research ·Jacques P. Brown, Richard L. Prince, Chad Deal, Robert R. Recker, Douglas P. Kiel, (unknown), Peyman Hadji, Lorenz C. Hofbauer, José María Álvaro‐Gracia, Huei Wang, Matthew Austin, Rachel B. Wagman, Richard Newmark, Cesar Libanati, Javier San Martín, Henry G. Bone	436

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact